Voyager Therapeutics (VYGR)
NASDAQ:VYGR
VYGR Stock Chart & Stats
$3.74
-$0.14(-2.36%)
At close: 4:00 PM EST
$3.74
-$0.14(-2.36%)
Day’s Range― - ―
52-Week Range$2.65 - $5.55
Previous CloseN/A
Volume91.62K
Average Volume (3M)555.04K
Market Cap
$222.90M
Enterprise Value$194.10M
Total Cash (Recent Filing)$196.45M
Total Debt (Recent Filing)$36.50M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
May 12, 2026EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding59,599,377
10 Day Avg. Volume458,729
30 Day Avg. Volume555,037
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.18
Price to Sales (P/S)5.71
P/FCF Ratio-1.71
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue4.81
Enterprise Value/Gross Profit4.81
Enterprise Value/Ebitda-1.55
Forecast
1Y Price Target
$14.67Price Target Upside292.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.82
Revenue Forecast (FY)$54.59M
Bulls Say, Bears Say
Bulls Say
Delivery Technology ValidationA partner initiating human testing of a gene therapy that uses Voyager's capsid engineered to cross the blood-brain barrier could provide first human validation of the brain delivery platform and increase confidence in program feasibility.
Partnerships And FinancingOngoing collaborations with large biopharma and potential partnerships around capsid and brain-shuttle technologies could deliver external validation, shared development risk and opportunities for non-dilutive financing.
Tau Imaging ReadoutsPlanned tau PET imaging results for the anti-tau antibody could demonstrate slowing of tau spread and serve as a biological proof-of-concept that supports further program advancement.
Bears Say
Biomarker-clinical DisconnectEvidence that reduced tau accumulation did not produce measurable cognitive benefit in prior studies underscores the risk that positive biomarker changes may not translate into meaningful patient outcomes.
Pipeline NarrowingPausing the APOE gene therapy program to reallocate resources reduces near-term pipeline diversity and concentrates development risk on remaining tau-focused programs.
Safety ConcernsObserved liver enzyme elevations and suspected cases of drug-induced liver injury in a tau antibody program raise tolerability concerns that could complicate dosing decisions and regulatory review.
Voyager Therapeutics News
VYGR FAQ
What was Voyager Therapeutics’s price range in the past 12 months?
Voyager Therapeutics lowest stock price was $2.65 and its highest was $5.55 in the past 12 months.
What is Voyager Therapeutics’s market cap?
Voyager Therapeutics’s market cap is $222.90M.
When is Voyager Therapeutics’s upcoming earnings report date?
Voyager Therapeutics’s upcoming earnings report date is May 12, 2026 which is in 29 days.
How were Voyager Therapeutics’s earnings last quarter?
Voyager Therapeutics released its earnings results on Mar 09, 2026. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.511 by $0.051.
Is Voyager Therapeutics overvalued?
According to Wall Street analysts Voyager Therapeutics’s price is currently Undervalued.
Does Voyager Therapeutics pay dividends?
Voyager Therapeutics does not currently pay dividends.
What is Voyager Therapeutics’s EPS estimate?
Voyager Therapeutics’s EPS estimate is -0.53.
How many shares outstanding does Voyager Therapeutics have?
Voyager Therapeutics has 59,599,377 shares outstanding.
What happened to Voyager Therapeutics’s price movement after its last earnings report?
Voyager Therapeutics reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.511. Following the earnings report the stock price went up 21.655%.
Which hedge fund is a major shareholder of Voyager Therapeutics?
Currently, no hedge funds are holding shares in VYGR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Voyager Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.67 (292.25% Upside)
$14.67 (292.25% Upside)
Hedge Fund Trend
Decreased
By 9.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $298.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.24%
12-Months-Change
Fundamentals
Return on Equity
-51.35%
Trailing 12-Months
Asset Growth
-35.81%
Trailing 12-Months
Company Description
Voyager Therapeutics
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
VYGR Stock 12 Month Forecast
Average Price Target
$14.67
▲(292.25% Upside)
Technical Analysis
Galectin Therapeutics
―
Cartesian Therapeutics
―
Silence Therapeutics
―
Tenaya Therapeutics
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
2.17% Insiders
10.74% Mutual Funds
22.37% Other Institutional Investors
55.70% Public Companies and
Individual Investors